Heart transplant (HTx) recipients usually have reduced exercise capacity with reported VO 2peak levels of 50-70% predicted value. Our hypothesis was that highintensity interval training (HIIT) is an applicable and safe form of exercise in HTx recipients and that it would markedly improve VO 2peak.Secondarily, we wanted to evaluate central and peripheral mechanisms behind a potential VO 2peak increase. Forty-eight clinically stable HTx recipients >18 years old and 1-8 years after HTx underwent maximal exercise testing on a treadmill and were randomized to either exercise group (a 1-year HIIT-program) or control group (usual care). The mean ± SD age was 51 ± 16 years, 71% were male and time from HTx was 4.1 ± 2.2 years. The mean VO 2peak difference between groups at follow-up was 3.6 [2.0, 5.2] mL/kg/min (p < 0.001). The exercise group had 89.0 ± 17.5% of predicted VO 2peak versus 82.5 ± 20.0 in the control group (p < 0.001). There were no changes in cardiac function measured by echocardiography. We have demonstrated that a long-term, partly supervised and community-based HIIT-program is an applicable, effective and safe way to improve VO 2peak , muscular exercise capacity and general health in HTx recipients. The results indicate that HIIT should be more frequently used among stable HTx recipients in the future.Key words: Aerobic exercise, chronotropic response, heart transplantation, maximum oxygen uptake, muscle strength, VO 2peak Abbreviations: % HR max , percent of age-predicted maximum heart rate; AT, anaerobic threshold (ventilatory threshold); BIA, bioelectrical impedance analysis; CG, control group; CO, cardiac output; CRI, chronotropic response index; CRP, C-reactive protein; DXA, dual-emission X-ray absorptiometry; EG, exercise group; eGFR, estimated glomerular filtration rate; Hb, hemoglobin; HF, heart failure; HIIT, high-intensity interval training; HR, heart rate; HR max , maximum heart rate; HRQoL, health-related quality of life; HTx, heart transplant; J, Joule; LV, left ventricle; LVe', left ventricle early diastolic mitral annular velocity; LVEF, left ventricle ejection fraction; Nm, Newtonmeter; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; RER, respiratory exchange ratio; RPE, rated perceived exertion; VAS scale, visual analog scale; VE max , maximum ventilation; VO 2peak , peak oxygen uptake.
Objective-Based on the emerging importance of the wingless (Wnt) pathways in inflammation and vascular biology, we hypothesized a role for Dickkopf-1 (DKK-1), a major modulator of Wnt signaling, in atherogenesis and plaque destabilization. Methods and Results-We report increased levels of DKK-1 in experimental (ApoE Ϫ/Ϫ mice) and clinical (patients with coronary artery disease ͓nϭ80͔ and patients with carotid plaque ͓nϭ47͔) atherosclerosis, both systemically (serum) and within the lesion, with particularly high levels in advanced and unstable disease. We identified platelets as an important cellular source of DKK-1 as shown by in vitro experiments and by immunostaining of thrombus material obtained at the site of plaque rupture in patients with acute ST-elevation myocardial infarction, with strong immunoreactivity in platelet aggregates. Our in vitro experiments identified a role for platelet-and endothelialderived DKK-1 in platelet-dependent endothelial activation, promoting enhanced release of inflammatory cytokines. These inflammatory effects of DKK-1 involved inhibition of the Wnt/-catenin pathway and activation of nuclear factor B. Key Words: atherosclerosis Ⅲ endothelium Ⅲ inflammation Ⅲ platelets P roteins from the wingless (Wnt) signaling pathways are involved in diverse developmental and physiological processes, including cardiac and vascular development. Wnt signals are transduced to the canonical and the noncanonical pathways for control of cell fate, cell movement, and tissue polarity. 1 The Wnt pathways are regulated by multiple families of secreted antagonists including soluble frizzled related receptors and dickkopfs (DKK). The best studied of these is DKK-1, which dampens Wnt signaling by binding to the low-density lipoprotein receptor-related protein (LRP)5/6 and a cell surface coreceptor, Kremen-1, promoting internalization of the receptor complex. 2 In adults, DKK-1 has been implicated in bone disease, cancer, and brain ischemia, and most recently, the destructive effect of tumor necrosis factor ␣ (TNF␣) on joints in rheumatoid arthritis was found to involve DKK-1. 2,3 Also, serum levels of DKK-1 give prognostic information in patients with multiple myeloma and other malignancies as well as in patients with osteoarthritis. 4,5 Recent evidence points to an important role of the Wnt signaling pathways in the regulation of inflammation. Thus, activation of the canonical Wnt/-catenin pathway induces proliferation and survival of endothelial cells, enhances monocyte adhesion, and regulates transendothelial migration of monocytes. 6 -9 Moreover, activation of the noncanonical pathway has been shown to regulate inflammatory responses of human monocytes and macrophages in vitro. 10,11 However, the interaction between the different proteins in the Wnt family is rather complex, and the role Conclusion-Our
Rabbit monoclonal antibodies are reliable markers of SSTRs in somatotroph adenomas. SSTR2a expression correlated with the response to octreotide and was reduced after octreotide treatment, indicating the need for adjustment when SSTR2a expression is correlated with baseline characteristics. Evaluation of SSTR subtypes may be an important aspect of improving the medical treatment for acromegaly.
Context: Appropriate cell-to-cell adhesion is fundamental for the epithelial phenotype of pituitary cells. Loss of the adhesion protein E-cadherin has been associated with invasiveness, metastasis, and poor prognosis in cancers of epithelial origin. In somatotroph adenomas, a variable and reduced expression of E-cadherin has been demonstrated. In addition, nuclear translocation of E-cadherin was found to correlate with pituitary tumor invasion. Objective: The objective was to examine the protein expression of E-cadherin in somatotroph pituitary adenomas in relation to adenoma size, invasiveness, and somatostatin analog (SMS) efficacy. Patients and Methods: Eighty-three patients were included, and 29 were treated preoperatively with SMS. Adenoma E-cadherin protein expression was analyzed by Western blot (61 patients) and immunohistochemistry (IHC) (80 patients) with antibodies directed against both extracellular and intracellular domains (IHC). The acute (direct surgery group) and long-term (preoperatively treated group) SMS responses were evaluated. Baseline tumor volume and invasiveness were measured on magnetic resonance imaging scans. Results: Membranous E-cadherin was lost in several adenomas. Nine of these were nuclear E-cadherin positive. The E-cadherin protein expression correlated negatively to tumor size and positively to acute SMS response. Low E-cadherin levels (preoperatively treated group only) and loss of membranous E-cadherin correlated to tumor invasiveness. The E-cadherin level correlated positively to tumor reduction after SMS treatment, and adenomas with nuclear E-cadherin staining had lower IGF-I reduction and tumor shrinkage. Preoperatively treated adenomas had reduced E-cadherin protein levels, but the IHC expression was unaltered. Conclusion: Reduced E-cadherin expression may correlate to a dedifferentiated phenotype in the somatotroph pituitary adenomas.
With increasing rates of obesity and new diagnostic criteria for gestational diabetes mellitus (GDM), the overall prevalence of GDM is increasing worldwide. Women with GDM have an increased risk of maternal and fetal complications during pregnancy as well as long-term risks including higher prevalence of type 2 diabetes mellitus and cardiovascular disease. In recent years, the role of immune activation and inflammation in the pathogenesis of GDM has gained increasing attention. This monograph explores the current state of the literature as regards the expression of markers of inflammation in the maternal circulation, placenta, and adipose tissue of women with GDM.
Summary:Purpose: Long-term treatment with antiepileptic drugs (AEDs) is associated with increased risk of fractures. Phenytoin (PHT) and valproate (VPA) have both been suggested to influence bone health, whereas levetiracetam (LEV) is scarcely studied. The present study compares the effect of these AEDs on bone mass, biomechanical strength, and bone turnover in rats.Methods: Female rats received PHT (50mg/kg), VPA (300mg/kg), or LEV (50 and 150mg/kg) for 90 days. Dissected femurs were analyzed using dual energy x-ray absorptiometry (DXA), three-point cantilever bending, and histomorphological evaluation. Serum levels of biochemical bone turnover markers were monitored using immunoassay quantification.Results: PHT and VPA reduced bone mineral density (BMD) and content (BMC) in one or more bone compartments, whereas LEV did not. VPA induced increased bone turnover, whereas modest changes were observed for PHT. Interestingly, low-dose LEV was associated with reduced biomechanical strength of the femoral neck (mainly trabecular bone). In addition, low-dose LEV treatment resulted in significantly reduced levels of serum osteocalcin, a marker of bone formation. Histomorphological analyses indicated increased retention of cartilage remnants at the growth plate metaphysis of rats treated with low-dose LEV vs. controls.Conclusions: PHT, VPA, and LEV exert differential effects on bone mass and strength, suggesting different mechanisms of action. The weakening effect of low-dose LEV on the femoral neck, despite a constant BMD, suggests a primary effect on bone quality. These findings warrant further human studies of possible adverse effects of LEV on bone development and growth, particularly in children and adolescents.
These results indicate that ESRP1 could be a master regulator of the EMT process in pituitary adenomas causing acromegaly.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.